Cost-effectiveness of avelumab first-line maintenance therapy for adult patients with locally advanced or metastatic urothelial carcinoma in France.

Date publication

mai 2024

Journal

PloS one

Auteurs

Membres identifiés du Cancéropôle Est :
Dr THIERY-VUILLEMIN Antoine

Tous les auteurs :
Porte F, Granghaud A, Chang J, Kearney M, Morel A, Plessala I, Cawston H, Roiz J, Xiao Y, Solbes MN, Lambert P, Ravaud A, Loriot Y, Thiery-Vuillemin A, Lévy P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38728337

Résumé

This study evaluated the cost-effectiveness of avelumab first-line (1L) maintenance therapy plus best supportive care (BSC) versus BSC alone for adults with locally advanced or metastatic urothelial carcinoma (la/mUC) that had not progressed following platinum-based chemotherapy in France.

Mots clés

Humans, Antibodies, Monoclonal, Humanized, economics, France, Cost-Benefit Analysis, Male, Female, Urinary Bladder Neoplasms, drug therapy, Quality-Adjusted Life Years, Aged, Middle Aged, Adult, Carcinoma, Transitional Cell, drug therapy, Neoplasm Metastasis, Urologic Neoplasms, drug therapy, Maintenance Chemotherapy, economics

Référence

PLoS One. 2024 05 10;19(5):e0302548